Combined effect of fasting blood glucose and serum uric acid on nonalcoholic fatty liver disease

Table 4 NAFLD ORs (95% CIs) in relation to FBG and SUA in participants without self-reported T2DM

T2DM-free participants		No. of subjects	No. of Cases	Basic-adjusted OR (95%CI) ^a	Multi-adjusted OR (95%CI) ^b
Fasting				1.89 (1.78–2.02)	1.49 (1.39–1.60)
< 6		10,058	3523	Reference	Reference
6–7		696	424	2.72 (2.31–3.20)	1.97 (1.62–2.41)
≥ 7		326	228	3.88 (3.04–4.95)	2.86 (2.12–3.86)
Uric Acid				1.62 (1.56–1.67)	1.38 (1.33–1.44)
Normal		8153	2479	Reference	Reference
Hyperuricemia		2917	1692	2.94 (2.68–3.21)	2.04 (1.83–2.27)
Fasting	Uric Acid
< 6	Normal	7435	2063	Reference	Reference
6–7	Normal	477	260	2.81 (2.32–3.40)	2.02 (1.60–2.55) ^*
≥ 7	Normal	241	156	4.06 (3.09–5.33)	2.99 (2.61–5.43) ^**
< 6	Hyperuricemia	2615	1458	3.00 (2.73–3.29)	2.08 (1.85–2.32)
6–7	Hyperuricemia	217	162	6.88 (5.04–9.41)	3.77 (2.61–5.43) ^*
≥ 7	Hyperuricemia	85	72	13.67 (7.54–24.80)	7.87 (3.57–17.34) ^**

^a Adjusted age and sex
^b Adjusted age, sex, education, smoking, drinking, physical exercise, body mass index, hypertension, and total cholesterol
^* Measures of additive interaction for nonalcoholic fatty liver disease:
Relative excess risk due to interaction: 0.687, 95%CI: -0.753-2.317, P > 0.05;
Attributable proportion: 0.182, 95%CI: -0.139-0.604, P > 0.05;
Synergy index: 1.330, 95%CI: 0.772–2.290, P > 0.05
^** Measures of additive interaction for nonalcoholic fatty liver disease:
Relative excess risk due to interaction: 3.820, 95%CI: -2.405-10.045, P > 0.05;
Attributable proportion: 0.488, 95%CI: 0.068–0.909, P = 0.02;
Synergy index: 2.272, 95%CI: 0.873–5.911, P > 0.05

ISSN: 1476-511X